References

1. Demiroğlu YZ. Difteri-boğmaca ve tetanoz aşıları. In: Şenol E, Acar A, Alp Çavuş S, Erol Ç, editors. Erişkin bağışıklamasında pratik bilgiler. İstanbul: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği; 2021. p. 6-141.
2. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC). [erişim 20 Eylül 2024]. https://www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf
3. Don’t be guilty of these preventable errors in vaccine administration! [Internet]. Saint Paul (MN): Immunize.org. [erişim 20 Eylül 2024]. https://www.immunize.org/wp-content/uploads/catg.d/p3033.pdf
4. Chitlaru T, Israeli M, Bar-Haim E, et al. Next-generation Bacillus anthracis live attenuated spore vaccine based on the htrA(-) (High temperature requirement A) sterne strain. Sci Rep. 2016;6:18908. [CrossRef]
5. Anthrax in Humans and Animals. 4th edition. Geneva: World Health Organization (WHO); 2008. [erişim 20 Eylül 2024]. https://www.ncbi.nlm.nih.gov/books/NBK310486/
6. Information sheet: Observed rate of vaccine reactions, anthrax vaccines to humans. Geneva: World Health Organization (WHO); 2012. [erişim 20 Eylül 2024]. https://cdn.who.int/media/docs/default-source/pvg/global-vaccine-safety/anthrax-vaccine-rates-information-sheet.pdf?sfvrsn=984c7d5_4
7. Kotzé MJ. Prosthetic joint infection, dental treatment and antibiotic prophylaxis. Orthop Rev (Pavia). 2009;1(1):e7. [CrossRef] 
8. Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners–a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015;146(1):11-6.e8. [CrossRef] 
9. Tüberküloz tanı ve tedavi rehberi [Internet]. Ankara: T.C. Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü; 2019. [erişim 10 Haziran 2024]. https://hsgm.saglik.gov.tr/depo/birimler/tuberkuloz-db/Dokumanlar/Rehberler/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf
10. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012;54(6):784-91. [CrossRef] 
11. Şimşek-Yavuz S, Özger S, Benli A, et al. [The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) evidence-based guideline for the diagnosis and treatment of brucellosis, 2023]. Klimik Derg. 2023;36(2):86-123. Turkish. [CrossRef]
12. Brucellosis reference guide: exposures, testing, and prevention [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2017. [erişim 10 Haziran 2024]. https://www.cdc.gov/brucellosis/media/pdfs/2025/02/brucellosi-reference-guide.pdf
13. Tuncer A, Piri Çınar B, Bilge N, et al. Vaccination in individuals with multiple sclerosis – part II. Turk J Neurol. 2023;29:85-94. [CrossRef]
14. Kimura H, Kwong YL. EBV viral loads in diagnosis, monitoring, and response assessment. Front Oncol. 2019;9:62. [CrossRef] 
15. Yu S, Yang Q, Wu J, et al. Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: A cohort study. J Infect. 2021;82(1):105-11. [CrossRef]
16. Pneumococcal vaccine recommendations [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2024. [erişim 10 Haziran 2024]. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
17. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-75. Erratum in: MMWR Morb Mortal Wkly Rep. 2020;68(5152):1195. [CrossRef] 
18. Committee on Infectious Diseases, American Academy of Pediatrics. Red Book: 2024–2027 report of the Committee on Infectious Diseases. 33rd ed. Itasca (IL): American Academy of Pediatrics; 2024.
19. Kucharzik T, Ellul P, Greuter T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021;15(6):879-913. Erratum in: J Crohns Colitis. 2023;17(1):149. [CrossRef]
20. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023;75(3):449-64. [CrossRef]
21. Erkoç MF, Öztoprak B, Alkan S, Okur A. A rare cause of pleural effusion: ruptured primary pleural hydatid cyst. BMJ Case Rep. 2014;2014:bcr2013202959. [CrossRef]
22. WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull World Health Organ. 1996;74(3):231-42.
23. Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet. 1993;342(8882):1269-72. [CrossRef] 
24. Manterola C, Mansilla JA, Fonseca F. Preoperative albendazole and scolices viability in patients with hepatic echinococcosis. World J Surg. 2005;29(6):750-3. [CrossRef] 
25. Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010;114(1):1-16. [CrossRef]
26. Brunetti E, Tamarozzi F. Watch-and-wait approach for inactive echinococcal cysts: scoping review update since the issue of the WHO-IWGE Expert Consensus and current perspectives. Curr Opin Infect Dis. 2023;36(5):326-32. [CrossRef]
27.  Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: Advances in the 21st century. Clin Microbiol Rev. 2019;32(2):e00075-18. [CrossRef]
28. Petersen PT, Bodilsen J, Jepsen MPG, et al; Danish Study Group of Infections of the Brain (DASGIB). Dexamethasone in adults with viral meningitis: an observational cohort study. Clin Microbiol Infect. 2025;31(1):87-92. [CrossRef]
29. Meyding-Lamadé U, Jacobi C, Martinez-Torres F, et al. The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial. Neurol Res Pract. 2019;1:26. [CrossRef]
30. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-247. [CrossRef]
31. Bernard A, Koeppen M. [Extracorporeal procedures in sepsis]. Anaesthesiologie. 2024;73(10):713-20. German. Erratum in: Anaesthesiologie. 2025;74(6):397. [CrossRef]
32. Chen JJ, Lai PC, Lee TH, Huang YT. Blood purification for adult patients with severe infection or sepsis/septic shock: a network meta-analysis of randomized controlled trials. Crit Care Med. 2023;51(12):1777-89. [CrossRef]
33. van de Beek D, Cabellos C, Dzupova O, et al; ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62. [CrossRef]
34. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2013;(6):CD004405. Update in: Cochrane Database Syst Rev. 2015;(9):CD004405. [CrossRef]
35. Domingues R, Bruniera G, Brunale F, Mangueira C, Senne C. Lumbar puncture in patients using anticoagulants and antiplatelet agents. Arq Neuropsiquiatr. 2016;74(8):679-86. [CrossRef]
36. Dodd KC, Emsley HCA, Desborough MJR, Chhetri SK. Periprocedural antithrombotic management for lumbar puncture: Association of British Neurologists Clinical Guideline. Pract Neurol. 2018;18(6):436-46. [CrossRef]
37. Carabenciov ID, Hawkes MA, Hocker S. Safety of lumbar puncture performed on dual antiplatelet therapy. Mayo Clin Proc. 2018;93(5):627-9. [CrossRef]
38. Stichaller L, Krajnc N, Leutmezer F, et al. Antiplatelet therapy is not associated with increased risk of complications after lumbar puncture. J Neurol. 2024;272(1):88. [CrossRef]
39. Lee PW, Levy M. Risk of hematoma from aspirin or clopidogrel owing to lumbar puncture. Mayo Clin Proc. 2019;94(8):1552-5. [CrossRef]
40. Nash M, Bloch S, Golan D. Safety of lumbar puncture for people who are treated with ADP receptor antagonists. J Neurol. 2023;270(6):3052-7. [CrossRef]
41. Botilismus [Internet]. Ankara: T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. [erişim 4 Haziran 2024]. https://hsgm.saglik.gov.tr/tr/hastaliklar/botilismus.html
42. Popovich KJ, Aureden K, Ham DC, et al. SHEA/IDSA/APIC Practice Recommendation: Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(7):1039-67. [CrossRef]
43. Miller LG, McKinnell JA, Singh RD, et al. Decolonization in nursing homes to prevent infection and hospitalization. N Engl J Med. 2023;389(19):1766-77. [CrossRef]
44. Smith M, Herwaldt L. Nasal decolonization: What antimicrobials and antiseptics are most effective before surgery and in the ICU. Am J Infect Control. 2023;51(11S):A64-A71. [CrossRef] 
45. Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. [CrossRef]
46. Sherer CR, Sprague BM, Campos JM, et al. Characterizing vancomycin-resistant enterococci in neonatal intensive care. Emerg Infect Dis. 2005;11(9):1470-2. [CrossRef]
47. McDonald LC, Garza LR, Jarvis WR. Proficiency of clinical laboratories in and near Monterrey, Mexico, to detect vancomycin-resistant enterococci. Emerg Infect Dis. 1999;5(1):143-6. [CrossRef]
48. Mammina C, Di Noto AM, Costa A, Nastasi A. VanB-VanC1 Enterococcus gallinarum, Italy. Emerg Infect Dis. 2005;11(9):1491-2. [CrossRef]
49. Arias CA, Miller WR. Mechanisms of antibiotic resistance in enterococci [Internet]. Waltham (MA): UpToDate; 2023. [erişim 5 Ağustos 2024]. https://www.uptodate.com/contents/mechanisms-of-antibiotic-resistance-in-enterococci
50. Pierce J, Edmond M, Stevens MP. Guide to infection control in the healthcare setting: Enterococcal species [Internet]. Brookline (MA): International Society for Infectious Diseases (ISID); 2018. [erişim 5 Ağustos 2024]. https://isid.org/wp-content/uploads/2019/07/ISID_GUIDE_ENTEROCOCCAL_SPECIES.pdf
51. Dokümanlar [Internet]. Ankara: T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Bulaşıcı Hastalıklar ve Erken Uyarı Dairesi Başkanlığı. [erişim 10 Mart 2025]. https://hsgm.saglik.gov.tr/tr/dokumanlar-bulasicihastaliklar.html
52. Diyaliz Merkezlerinde Enfeksiyon Kontrolüne Yönelik Tedbirler Genelgesi 2016/20 [Internet]. Ankara T.C. Sağlık Bakanlığı Tedavi Hizmetleri Genel Müdürlüğü. [erişim 10 Şubat 2024]. https://dosyasb.saglik.gov.tr/Eklenti/48409/0/diyaliz-merkezlerinde-enfeksiyon-kontrolune-yonelik-tedbirler-genelgesipdf.pdf?
53. Martin P, Awan AA, Berenguer MC, et al. Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int. 2022;102(6):1228-37. [CrossRef]
54. Sağlık hizmetlerinde Candida auris [Internet]. Ankara: T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. [erişim 5 Temmuz 2025]. https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastaliklar-ve-erken-uyari-db/Dokumanlar/Afisler%20Brosurler/2025/Ek_Saglik_Hizmetlerinde_C._auris.pdf
55. Isolation precautions guideline [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2023. [erişim 1 Mart 2025]. https://www.cdc.gov/infection-control/hcp/isolation-precautions/index.html
56. Infection prevention and control strategies for seasonal influenza in healthcare settings [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2025. [erişim 1 Mart 2025]. https://www.cdc.gov/flu/hcp/infection-control/healthcare-settings.html
57. Jain M, Vadboncoeur J, Garg SJ, Biswas J. Bacille Calmette-Guérin: An ophthalmic perspective. Surv Ophthalmol. 2022;67(2):307-20. [CrossRef]
58. Tokano M, Tarumoto N, Imai K, et al. Acute tenosynovitis following an accidental injection of Bacille Calmette-Guérin (BCG) in a health care worker: A case report. Infect Prev Pract. 2023;6(1):100332. [CrossRef]
59. Macaigne H, Ruggieri VG, L Vallet-Tadeusz, et al. Are systematic drain tip or drainage fluid cultures predictive of surgical site infections? J Hosp Infect. 2019;102(3):245-55. [CrossRef]
60. De Waele JJ, Boelens J, Van De Putte D, Huis In ‘t Veld D, Coenye T. The role of abdominal drain cultures in managing abdominal infections. Antibiotics (Basel). 2022;11(5):697. [CrossRef]
61. Sethi DK, Webber MA, Mishra EK. Indwelling pleural catheter infection and colonisation: a clinical practice review. J Thorac Dis. 2024;16(3):2196-204. [CrossRef]
62. Pogue JM, Jones RN, Bradley JS, et al. Polymyxin susceptibility testing and interpretive breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrob Agents Chemother. 2020;64(2):e01495-19. [CrossRef]
63. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):R27. [CrossRef]
64. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14. [CrossRef]
65. Şimşek-Yavuz S, Akar AR, Aydoğdu S, et al. [Diagnosis, treatment and prevention of infective endocarditis: Turkish Consensus Report]. Klimik Derg. 2019; 32(Suppl. 1): 2-116. Turkish. [CrossRef]
66. Sayin Kutlu S, Saçar S, Süzer T, et al. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam]. Mikrobiyol Bul. 2008;42(2):353-8. Turkish. 
67. Stahl JP, Bru JP, Fredj G, Brammer KW, Malleret MR, Micoud M. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis. 1986;8 Suppl 5:S612-6. [CrossRef]
68. Sipahi OR, Mermer S, Demirdal T, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: Results of the Ege study. Clin Neurol Neurosurg. 2018;172:31-8. [CrossRef]
69. Polat M, Ozkaya-Parlakay A. Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii. Eur J Pediatr. 2019;178(1):117-8. [CrossRef]
70. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53(11):4907-10. [CrossRef]
71. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. [CrossRef]
72. Fisher JF, Sobel JD, Kauffman CA, Newman CA. Candida urinary tract infections–treatment. Clin Infect Dis. 2011;52 Suppl 6:S457-66. [CrossRef]
73. Capilla-Miranda A, Plaza-López D, Garcia-Clemente P, Baquero-Artigao F. Intermittent bladder irrigation with liposomal amphotericin B for the treatment of fluconazole-resistant Meyerozyma guilliermondii cystitis in an immunosuppressed adolescent. Enferm Infecc Microbiol Clin (Engl Ed). 2023;41(4):253-4. [CrossRef]
74. Tabah A, Laupland KB. Update on Staphylococcus aureus bacteraemia. Curr Opin Crit Care. 2022;28(5):495-504. [CrossRef]
75. Horino T, Hori S. Metastatic infection during Staphylococcus aureus bacteremia. J Infect Chemother. 2020;26(2):162-9. [CrossRef]
76. Heriot GS, Cronin K, Tong SYC, Cheng AC, Liew D. Criteria for identifying patients with Staphylococcus aureus bacteremia who are at low risk of endocarditis: a systematic review. Open Forum Infect Dis. 2017;4(4):ofx261. [CrossRef]
77. Brusch JL. Infective endocarditis [Internet]. Medscape; 2024. [erişim 5 Ağustos 2024]. https://emedicine.medscape.com/article/216650-overview
78. Xiao Y, Heck V, Hao L, Rauschmann M, Slavici A. Local antibiotic carriers in the surgical management of pyogenic spondylodiscitis: First comparative evaluation of gentamicin-loaded versus vancomycin-loaded efficacy. Orthopadie (Heidelb). 2025. [CrossRef]
79. Thavarajasingam SG, Vemulapalli KV, Vishnu K S, et al. Conservative versus early surgical treatment in the management of pyogenic spondylodiscitis: a systematic review and meta-analysis. Sci Rep. 2023;13(1):15647. [CrossRef]
80. Spernovasilis N, Karantanas A, Markaki I, et al. Brucella spondylitis: current knowledge and recent advances. J Clin Med. 2024;13(2):595. [CrossRef]
81. O’Donnell M, Orr PH. Infectious complications of intravesical BCG immunotherapy [Internet]. Waltham (MA): UpToDate; 2024. [erişim 15 Ocak 2025]. https://www.uptodate.com/contents/infectious-complications-of-intravesical-bcg-immunotherapy
82. Holmberg L, Skogmar S, Garmo H, et al. Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. BJU Int. 2024;134(2):229-38. [CrossRef]